Senti Biosciences, Inc. (NASDAQ:SNTI) CEO Sells $15,962.54 in Stock

Senti Biosciences, Inc. (NASDAQ:SNTI) CEO Timothy K. Lu sold 3,922 shares of Senti Biosciences stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $4.07, for a total transaction of $15,962.54. Following the transaction, the chief executive officer now owns 82,627 shares of the company’s stock, valued at approximately $336,291.89. The trade was a 4.53 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Senti Biosciences Trading Down 2.9 %

Shares of NASDAQ SNTI opened at $4.33 on Friday. Senti Biosciences, Inc. has a 12 month low of $1.52 and a 12 month high of $16.94. The company has a 50-day simple moving average of $4.57 and a 200-day simple moving average of $3.13.

Analyst Upgrades and Downgrades

Separately, Chardan Capital restated a “buy” rating and set a $10.00 target price on shares of Senti Biosciences in a research report on Monday, December 2nd.

About Senti Biosciences

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.